Photodynamic therapy based on combined use of 5-aminolevulinic acid with a pheophorbide-a derivative for murine tumors.
5-Aminolevulinic acid (5-ALA)-based photodynamic therapy (PDT) appears to be a promising cancer treatment modality. Here, we investigated whether enhancement of 5-ALA-PDT by combining another photosensitizer, a pheophorbide-a derivative (PH-1126), is an option. PH-1126 (2.5, 5 or 10 mg/kg.bw) and 5-ALA (168 mg/kg.bw) were injected i.p. into C3H/HeN mice bearing squamous cell carcinoma (SCC) or BALB/c nude mice bearing L5178Y lymphoma. Afterwards, these mice received laser irradiations (630 nm for 5-ALA and 650 nm for PH-1126) with a total dose of 88 J/cm2. The results showed that PDT with 5-ALA plus PH-1126 at a low dose (2.5 mg/kg.bw) were well tolerated by both animal models, with resultant synergistically enhanced inhibition of tumor growth and/or survival advantage for the treated animals. This study demonstrated the usefulness of the combination of a low dose PH-1126 with 5-ALA for PDT of experimental tumors in vivo.